GVR Report cover Meningococcal Vaccine Market Size, Share & Trends Report

Meningococcal Vaccine Market Size, Share & Trends Analysis Report By Brand (Menactra, Menveo, Bexsero, Trumenba, Nimenrix), By Type (Bivalent, Quadrivalent), By Age Group, By Region, And Segment Forecasts, 2020 - 2027

  • Published Date: Sep, 2020
  • Base Year for Estimate: 2019
  • Report ID: GVR-4-68039-045-9
  • Format: Electronic (PDF)
  • Historical Data: 2016 - 2018
  • Number of Pages: 100

Report Overview

The global meningococcal vaccine market size was valued at USD 2.8 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 9.5% from 2020 to 2027. The increasing prevalence of meningitis is one of the major factors expected to drive the market. According to the Centers for Disease Control and Prevention (CDC), around 1.2 million cases of bacterial meningitis are projected to occur globally every year. Increasing initiatives by government and regulatory authorities to combat the rising prevalence of meningitis is expected to boost the market growth. For instance, in May 2018, “Defeating meningitis by 2030” was introduced at the World Health Assembly by Eastern Mediterranean and African regions to develop a strategic roadmap for meningitis prevention by prioritizing areas for research and enhanced control activities.

The U.S. meningococcal vaccines market size

Furthermore, the presence of non-profit organizations providing funds for research projects, training to healthcare professionals, and offering information & support to patients is anticipated to accelerate market growth. For instance, the Meningitis Research Foundation has awarded 161 research grants and around USD 28.0 million investment in scientific researches. This organization brings people and expertise together to meet challenges in preventing meningitis.

In addition, the presence of phase III vaccines in the pipeline which are expected to be commercialized over the forecast period is anticipated to fuel market growth. For instance, MenACYW, a conjugate vaccine manufactured by Sanofi, is currently in phase III clinical trial.

Type Insights

Quadrivalent meningococcal vaccines accounted for the largest revenue share of 50.0% in 2019 owing to widely used brands such as Menactra, Menveo, and Nimenrix. Approval of new vaccines to protect people against meningococcal meningitis is anticipated to fuel the growth of this market. For instance, in April 2020, Sanofi received the U.S. FDA approval for MenQuadfi. It is a quadrivalent meningococcal (Groups A, C, Y, W) conjugate vaccine for prevention from invasive meningococcal disease in people 2 years and older.

The others segment consists of monovalent and pentavalent meningococcal vaccines. Key players developing new vaccines for underdeveloped and developing countries are anticipated to fuel market growth. For instance, Serum Institute of India Pvt. Ltd. is working on a pentavalent meningococcal conjugate vaccine and is expected to deliver it at an affordable price where the vaccine is needed the most.

Brand Insights

Bexsero accounted for the largest revenue share of 31.1% in 2019 owing to fewer doctor visits, lower cost, and reduced doses. For instance, in June 2018, the European Commission approved a reduced dose of Bexsero targeting serogroup B in infants as an alternative to 3 + 1 schedule. Furthermore, in January 2020, a study was published in the New England Journal of Medicine that demonstrated the impact of Bexsero on infants under the National Immunisation Programme. It was found that the meningococcal vaccine showed a 75.0% decrease in meningitis cases in the U.K. and Australia.

In addition, increasing demand for vaccines is expected to fuel the growth of the meningococcal vaccines market. For instance, GlaxoSmithKline plc (GSK) increased supply of Bexsero by an additional 200,000 doses for wholesalers, GP surgeries, and pharmacies in June 2017. GSK increased the delivery volume of Bexsero by five times in 2017 as compared to the 2016 supply volume in the Australian private market.

Rising government support to provide meningococcal vaccines at a lower cost is expected to fuel market growth. For instance, the Centers for Disease Control and Prevention has listed prices of meningococcal vaccines under the immunization program. The CDC price for Trumenba, Bexsero, Menactra, & Menveo is USD 108.95, 108.53, 93.45, & 76.02 respectively, while the private sector prices are USD 149.89, 170.75, 128.38, and 130.75 respectively.

Age Group Insights

The infant segment dominated the market and accounted for the largest revenue share of 69.9% in 2019. This is expected to be the fastest-growing segment over the forecast period owing to the rising prevalence of meningitis and studies showing a reduction in meningitis cases. For instance, according to the European Centre for Disease Prevention and Control (ECDC), in 2017, IMD incidence was observed to be the highest in infants. In Europe, there were 8.2 confirmed cases per 100,000 population in children of age below one year.

Global meningococcal vaccines market share

In addition, the government is taking initiatives to replace the current meningitis C vaccine with new vaccines to combat rising deaths due to meningitis. For instance, in May 2019, the Ministry of Health of Ireland approved the menACWY vaccine to be provided to thousands of children & adults in Ireland due to rising cases of meningitis that were reported in 2018. Such initiatives are anticipated to boost the revenue of new meningococcal vaccines, which, in turn, will drive the market.

Regional Insights

North America dominated the market and accounted for a revenue share of 47.9% in 2019, followed by Europe. Favorable recommendations and support from government and high investments in R&D are some factors driving the North American market. For instance, in December 2019, NACI (National Advisory Committee on Immunization) published scientific information and recommendation on MenB-fHBP (bivalent factor-H binding protein meningococcal serogroup B) vaccine (Trumenba).

In Asia Pacific, the market is expected to grow at a significant rate during the forecast period. The increasing pediatric population and increasing initiatives by the government to combat the rising prevalence of the disease are contributing to the growth of meningococcal vaccines in this region.

Key Companies & Market Share Insights

The presence of a strong pipeline of meningococcal vaccines is expected to maintain a significant market share of the key players. For instance, Pfizer has developed a new molecular entity named PF-06886992 for Serogroups ABCWY Meningococcal Infections which is currently in Phase II clinical trials. Some of the prominent players in the meningococcal vaccine market include:

  • Pfizer Inc.

  • Novartis AG

  • Sanofi

  • Serum Institute of India Ltd.

  • GlaxoSmithKline plc.

  • Merck & Co., Inc.

Meningococcal Vaccine Market Report Scope

Report Attribute


Market size value in 2020

USD 3.2 billion

Revenue forecast in 2027

USD 5.9 billion

Growth Rate

CAGR of 9.5% from 2020 to 2027

Base year for estimation


Historical data

2016 - 2018

Forecast period

2020 - 2027

Quantitative units

Revenue in USD million and CAGR from 2020 to 2027

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Type, brand, age group, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

The U.S.; Canada; Germany; The U.K.; France; Italy; Spain; Russia; Japan; China; India; Australia; Singapore; South Korea; Brazil; Mexico; Argentina; Saudi Arabia; South Africa; UAE

Key companies profiled

Pfizer Inc.; Sanofi; Serum Institute of India Ltd.; GlaxoSmithKline plc; Merck & Co., Inc.

Customization scope

Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-markets from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global meningococcal vaccine market on the basis of type, brand, age group, and region:

  • Type Outlook (Revenue, USD Million, 2016 - 2027)

    • Bivalent

    • Quadrivalent

    • Others

  • Brand Outlook (Revenue, USD Million, 2016 - 2027)

    • Menactra

    • Menveo

    • Nimenrix

    • Trumenba

    • Bexsero

    • Others

  • Age Group Outlook (Revenue, USD Million, 2016 - 2027)

    • Infants (0 to 2 years)

    • Children and Adults (2 years & above)

  • Regional Outlook (Revenue, USD Million, 2016 - 2027)

    • North America

      • The U.S

      • Canada

    • Europe

      • Germany

      • The U.K.

      • France

      • Italy

      • Spain

      • Russia

    • Asia Pacific

      • Japan

      • China

      • India

      • Australia

      • Singapore

      • South Korea

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • Middle East & Africa

      • Saudi Arabia

      • South Africa

      • UAE

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.